Therapeutic drug monitoring (TDM) of biologics is a rapidly evolving field. We aimed to
provide a consensus statement regarding the clinical utility of TDM for biologics in …

Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …

Ulcerative colitis [UC] is a chronic inflammatory bowel disease [IBD] characterised by colonic
inflammation extending to a variable extent from the rectum. Care of the patient with UC …

Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimising the use of
biologics, and in particular anti-tumour necrosis factor (anti-TNF) therapy, in inflammatory …

Introduction: Biologic therapy has revolutionized the treatment of immune mediated
inflammatory diseases (IMID), such as inflammatory bowel disease (IBD), rheumatoid and …

The implementation of therapeutic drug monitoring (TDM) in the inflammatory bowel disease
practice has evolved over the years. In the early days, the focus was merely on measuring …

Biologic therapies have revolutionized the management of inflammatory bowel disease
[IBD], but primary and secondary non-responses occur in a significant proportion of patients …

Abstract Background and Aims Subcutaneous [SC] vedolizumab presents the opportunity for
inflammatory bowel disease [IBD] patients to manage their treatment at home. There are …

Objective The anti-α4β7 integrin antibody vedolizumab is administered at a fixed dose for
the treatment of IBDs. This leads to a wide range of serum concentrations in patients and …

Background The best option between vedolizumab and ustekinumab after anti‐tumour
necrosis factor (TNF) failure remains unclear in Crohn's disease. Aims To compare the short …